Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2015, Article ID 938628, 11 pages
http://dx.doi.org/10.1155/2015/938628
Clinical Study

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

1Desmond Tutu HIV Foundation, UCT Medical School, P.O. Box 13801, Mowbray, Cape Town 7705, South Africa
2Private Practice, 3535 San Dimas Street, Suite 24, Bakersfield, CA 93301, USA
3Parexel International, University of the Free State, Campus Avenue South, Bloemfontein, Free State 9301, South Africa
4Janssen Research & Development LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560-0200, USA
5Janssen Infectious Diseases BVBA, Turnhoutseweg 30, 2340 Beerse, Belgium

Received 11 September 2014; Revised 26 November 2014; Accepted 9 December 2014

Academic Editor: Andrea Mangano

Copyright © 2015 Catherine Orrell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “DHHS guidelines, Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents,” Department of Health and Human Services, 2014, http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf.
  2. H. F. Günthard, J. A. Aberg, J. J. Eron et al., “International Antiviral Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel,” The Journal of the American Medical Association, vol. 312, no. 4, pp. 410–425, 2014. View at Google Scholar
  3. BHIVA, “British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.),” HIV Medicine, vol. 15, supplement 1, pp. 1–85, 2014. View at Publisher · View at Google Scholar
  4. EACS, “European Guidelines for treatment of HIV infected adults in Europe,” Version 7.1, 2014, http://www.eacsociety.org/Portals/0/140601 EACS%20EN7.02.pdf.
  5. M. Schöller-Gyüre, B. Woodfall, T. De Marez et al., “Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir,” in Proceedings of the 8th International Congress on Drug Therapy in HIV Infection, Poster P278, Glasgow, UK, November 2006.
  6. T. N. Kakuda, M. Schöller-Gyüre, C. Workman et al., “Single- and multiple-dose pharmacokinetics of etravirine administered as two different formulations in HIV-1-infected patients,” Antiviral Therapy, vol. 13, no. 5, pp. 655–661, 2008. View at Google Scholar · View at Scopus
  7. D. González de Requena, O. Gallego, L. Valer, I. Jiménez-Nácher, and V. Soriano, “Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient,” AIDS Research and Human Retroviruses, vol. 20, no. 3, pp. 275–278, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Wu, Y. Huang, E. P. Acosta et al., “Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherence,” Journal of Pharmacokinetics and Pharmacodynamics, vol. 33, no. 4, pp. 399–419, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Barrios, A. L. Rendón, O. Gallego et al., “Predictors of virological response to atazanavir in protease inhibitor-experienced patients,” HIV Clinical Trials, vol. 5, no. 4, pp. 201–205, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Winston, M. Bloch, A. Carr et al., “Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy,” Journal of Antimicrobial Chemotherapy, vol. 56, no. 2, pp. 380–387, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Gianotti, E. Seminari, M. Guffanti et al., “Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir,” New Microbiologica, vol. 28, no. 2, pp. 119–125, 2005. View at Google Scholar · View at Scopus
  12. I. Pellegrin, D. Breilh, J.-M. Ragnaud et al., “Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study),” Antiviral Therapy, vol. 11, no. 4, pp. 421–429, 2006. View at Google Scholar · View at Scopus
  13. R. M. M. Cleijsen, M. E. Van de ende, F. P. Kroon et al., “Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice,” Journal of Antimicrobial Chemotherapy, vol. 60, no. 4, pp. 897–900, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Solas, P. Colson, I. Ravaux et al., “The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients,” Journal of Acquired Immune Deficiency Syndromes, vol. 48, no. 2, pp. 177–180, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. J. Bertz, A. Persson, E. Chung et al., “Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve,” Pharmacotherapy, vol. 33, no. 3, pp. 284–294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Goutell, T. Baudry, M.-C. Gagnieu et al., “Pharmacokinetic-pharmacodynamic modeling of unboosted atazanavir in a cohort of stable HIV-infected patients,” Antimicrobial Agents and Chemotherapy, vol. 57, no. 1, pp. 517–523, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. J. V. Madruga, P. Cahn, B. Grinsztejn et al., “Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 370, no. 9581, pp. 29–38, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Lazzarin, T. Campbell, B. Clotet et al., “Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 370, no. 9581, pp. 39–48, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Katlama, R. Haubrich, J. Lalezari et al., “Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials,” AIDS, vol. 23, no. 17, pp. 2289–2300, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. C. Katlama, B. Clotet, A. Mills et al., “Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials,” Antiviral Therapy, vol. 15, no. 7, pp. 1045–1052, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. T. N. Kakuda, J. R. Wade, E. Snoeck et al., “Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients,” Clinical Pharmacology and Therapeutics, vol. 88, no. 5, pp. 695–703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. A.-M. Taburet, C. Piketty, C. Chazallon et al., “Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 6, pp. 2091–2096, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. T. N. Kakuda, M. Schöller-Gyüre, G. De Smedt et al., “Assessment of the steady-state pharmacokinetic interaction between etravirine administered as two different formulations and tenofovir disoproxil fumarate in healthy volunteers,” HIV Medicine, vol. 10, no. 3, pp. 173–181, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Schöller-Gyüre, T. N. Kakuda, V. Sekar et al., “Pharmacokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers,” Antiviral Therapy, vol. 12, no. 5, pp. 789–796, 2007. View at Google Scholar · View at Scopus
  25. V. J. Sekar, E. Lefebvre, T. de Marez et al., “Pharmacokinetics of darunavir (TMC114) and atazanavir during coadministration in HIV-negative, healthy volunteers,” Drugs in R & D, vol. 8, no. 4, pp. 241–248, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. NIAID, “Division of AIDS table for grading the severity of adult and pediatric adverse events—version 1,” 2004, http://rsc.tech-res.com/Document/safetyandpharmacovigilance/Table_for_Grading_Severity_of_Adult_Pediatric_Adverse_Events.pdf.
  27. L. Tambuyzer, H. Azijn, L. T. Rimsky et al., “Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors,” Antiviral Therapy, vol. 14, no. 1, pp. 103–109, 2009. View at Google Scholar · View at Scopus
  28. V. A. Johnson, V. Calvez, H. F. Günthard et al., “2011 update of the drug resistance mutations in HIV-1,” Topics in Antiviral Medicine, vol. 19, no. 4, pp. 156–164, 2011. View at Google Scholar · View at Scopus
  29. A. Jetter, G. Fätkenheuer, D. Frank et al., “Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?” Antiviral Therapy, vol. 15, no. 7, pp. 975–983, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Dickinson, M. Boffito, D. Back et al., “Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers,” Journal of Antimicrobial Chemotherapy, vol. 63, no. 6, pp. 1233–1243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. D. R. Malan, E. Krantz, N. David, V. Wirtz, J. Hammond, and D. McGrath, “Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients,” Journal of Acquired Immune Deficiency Syndromes, vol. 47, no. 2, pp. 161–167, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. D. R. Malan, E. Krantz, N. David et al., “96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients,” Journal of the International Association of Physicians in AIDS Care, vol. 9, no. 1, pp. 34–42, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Johnson, B. Grinsztejn, C. Rodriguez et al., “Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures,” AIDS, vol. 19, no. 7, pp. 685–694, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Cohen, L. Nieto-Cisneros, C. Zala et al., “Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial,” Current Medical Research and Opinion, vol. 21, no. 10, pp. 1683–1692, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Zajdenverg, T. J. Podsadecki, S. Badal-Faesen et al., “Similar safety and efficacy of once-and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks,” Journal of Acquired Immune Deficiency Syndromes, vol. 54, no. 2, pp. 143–151, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Vingerhoets, L. Tambuyzer, H. Azijn et al., “Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies,” AIDS, vol. 24, no. 4, pp. 503–514, 2010. View at Publisher · View at Google Scholar · View at Scopus